ASPM and cholangiocarcinoma: The above results indicated that the C761Y mutation reduced the binding ability of RBM10 and SRSF2, leading to a decrease in ASPM exon18 ES event, an increase in ASPM203 expression, an enhancement of DVL2 stability, an upregulation of Wnt pathway, and a promotion of cholangiocarcinoma progression (Fig. 8.